CR Double-Crane Unit Clears GMP Inspection for Diabetes Drug Line

MT Newswires Live11-14

China Resources Double-Crane Pharmaceutical (SHA:600062) said its subsidiary Shuanghe Tian'an Pharmaceutical (Guizhou) passed a good manufacturing practice (GMP) compliance inspection for its metformin and empagliflozin tablets production line.

The inspection was conducted in Guiyang City, Guizhou Province, from Oct. 15 to Oct. 17, according to a Friday filing with the Shanghai Stock Exchange.

This marks the first pre-marketing GMP compliance inspection for the drug, which is used to improve glycemic control in adults with type 2 diabetes.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583523085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 12:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583523085","market":"sg","top_or_hot":-1,"title":"CR Double-Crane Unit Clears GMP Inspection for Diabetes Drug Line","media":"MT Newswires Live","content":"<html><body><p> China Resources Double-Crane Pharmaceutical (SHA:600062) said its subsidiary Shuanghe Tian'an Pharmaceutical (Guizhou) passed a good manufacturing practice (GMP) compliance inspection for its metformin and empagliflozin tablets production line.</p><p>The inspection was conducted in Guiyang City, Guizhou Province, from Oct. 15 to Oct. 17, according to a Friday filing with the Shanghai Stock Exchange.</p><p>This marks the first pre-marketing GMP compliance inspection for the drug, which is used to improve glycemic control in adults with type 2 diabetes.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Double-Crane Unit Clears GMP Inspection for Diabetes Drug Line</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Double-Crane Unit Clears GMP Inspection for Diabetes Drug Line\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-14 12:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China Resources Double-Crane Pharmaceutical (SHA:600062) said its subsidiary Shuanghe Tian'an Pharmaceutical (Guizhou) passed a good manufacturing practice (GMP) compliance inspection for its metformin and empagliflozin tablets production line.</p><p>The inspection was conducted in Guiyang City, Guizhou Province, from Oct. 15 to Oct. 17, according to a Friday filing with the Shanghai Stock Exchange.</p><p>This marks the first pre-marketing GMP compliance inspection for the drug, which is used to improve glycemic control in adults with type 2 diabetes.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0010","symbol_name":"央企","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2583523085","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583523085","pubTimestamp":1763094868,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China Resources Double-Crane Pharmaceutical  said its subsidiary Shuanghe Tian'an Pharmaceutical  passed a good manufacturing practice  compliance inspection for its metformin and empagliflozin tablets production line.The inspection was conducted in Guiyang City, Guizhou Province, from Oct. 15 to Oct. 17, according to a Friday filing with the Shanghai Stock Exchange.This marks the first pre-marketing GMP compliance inspection for the drug, which is used to improve glycemic control in adults with type 2 diabetes.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600062":"华润双鹤","BK0010":"央企","BK0028":"国家队","BK0239":"医药制造","BK0185":"二线龙头","BK0188":"融资融券","BK0175":"白马股"},"translate_title":"华润双鹤装置通过糖尿病药物生产线GMP检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600062":0.9},"content_text":"China Resources Double-Crane Pharmaceutical (SHA:600062) said its subsidiary Shuanghe Tian'an Pharmaceutical (Guizhou) passed a good manufacturing practice (GMP) compliance inspection for its metformin and empagliflozin tablets production line.The inspection was conducted in Guiyang City, Guizhou Province, from Oct. 15 to Oct. 17, according to a Friday filing with the Shanghai Stock Exchange.This marks the first pre-marketing GMP compliance inspection for the drug, which is used to improve glycemic control in adults with type 2 diabetes.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583523085","isCrawlerRequest":true}